Clinical trials: Cat Hypersensitivity
Cat Allergy
Phase III Cat-PAD Follow-on Study
The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment.
- Trial name
- NCT02040844
- Testing
- Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
- Volunteers
- 430 people
- Sponsor
- Circassia Limited
Rhinoconjunctivitis
Phase III Cat-PAD Study
The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.
- Trial name
- NCT01620762
- Testing
- Cat-PAD
- Where
- 118 sites in United States, Belgium and 7 more
- Volunteers
- 1,408 people
- Sponsor
- Circassia Limited
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Rhinoconjunctivitis
Paediatric Safety Study in Cat-PAD
Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects
- Trial name
- NCT01921257
- Testing
- Cat-PAD
- Where
- 3 sites in Poland
- Volunteers
- 16 people
- Sponsor
- Circassia Limited